Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 07:00 ET | Source: MediWound Ltd.

MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results

Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design study of EscharEx for...
February 18, 2020 08:00 ET | Source: MediWound Ltd.

MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020

YAVNE, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
January 13, 2020 08:00 ET | Source: MediWound Ltd.

MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States

YAVNE, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
January 06, 2020 06:30 ET | Source: MediWound Ltd.

BARDA Initiates the Procurement of NexoBrid for Emergency Response

YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the U.S....
January 02, 2020 07:30 ET | Source: MediWound Ltd.

MediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical

YAVNE, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
December 03, 2019 07:30 ET | Source: MediWound Ltd.

MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers

YAVNE, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in...
November 14, 2019 07:00 ET | Source: MediWound Ltd.

MediWound Reports Third Quarter 2019 Financial Results

Total revenues of $5.1 million, driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing...
November 06, 2019 08:00 ET | Source: MediWound Ltd.

MediWound to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 14

YAVNE, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
September 03, 2019 08:00 ET | Source: MediWound Ltd.

NexoBrid® Highlighted in 39 Presentations at the 18th European Burns Association Congress in Helsinki

YAVNE, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
August 13, 2019 07:00 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter 2019 Financial Results

Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid® license agreement BARDA committed additional $21 million to fund NexoBrid® expanded access...